4974 — Takara Bio Income Statement

0.000.00%

Last trade - 00:00

HealthcareBalancedMid CapFalling Star

Annual income statement for Takara Bio, fiscal year end - March 31st, JPY millions except per share, conversion factor applied.

	2020 March 31st	2021 March 31st	2022 March 31st	2023 March 31st	2024 March 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Yuho	Yuho	Yuho	Yuho	Yuho
Standards:	JAS	JAS	JAS	JAS	JAS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	34,565	46,086	67,699	78,142	43,505
Cost of Revenue
Gross Profit	21,106	31,872	49,211	44,765	26,908
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Other Operating Expenses
Total Operating Expenses	29,172	32,643	39,556	56,962	40,709
Operating Profit	5,393	13,443	28,143	21,180	2,796
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	5,433	13,552	27,532	21,224	2,853
Provision for Income Taxes
Net Income After Taxes	3,832	9,581	19,908	16,048	1,510
Minority Interest
Net Income Before Extraordinary Items
Net Income	3,821	9,547	19,850	16,013	1,481
Adjustments to Net Income
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Diluted Net Income	3,819	9,547	19,849	16,012	1,480
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	41.2	86.9	175	135	20
Dividends per Share